InSysBio's ASCPT 2022 Micro-Theater Session on YouTube

NEWS
Software
Publication
April 25, 2022

April 25, 2022

InSysBio has published the videos of its presentation in frames of Micro-Theater Session at ASCPT 2022 Annual Meeting on InSysBio YouTube channel. Oleg Demin, CEO of InSysBio, and Alexander Stepanov, Head of fIVE DB project, covered the topic of Online databases collecting and processing publicly available data that can help in calibration and validation of QSP models. 

The videos of the presentation:

Oleg Demin comments on the highlights of the talk, "Quantitative Systems Pharmacology (QSP) model is a complex biomathematical object representing our knowledge about structure and regulations of a biological system and PK/PD of a drug in terms of equations and parameter values. The model is primarily calibrated against available in vitro and in vivo data and then validated against in vivo and clinical data to provide coincidence of simulated response to a therapy with that measured clinically. Most of the data used for calibration/validation is available in public domain in form of quantitative information published in scientific articles. On the way of QSP model development a modeler may encounter substantial (technical) difficulties while working with quantitative data extracted from multiple sources. Indeed, in vitro data characterizing effect of regulatory molecules on cell dynamics processes should be converted to values of corresponding model parameters and ranges of the parameters should be estimated for proper description of variability in patient response. Baseline in vivo cytokine and cell concentrations are often measured in different units and for different patient groups with various demographic and disease-associated characteristics. These features make it difficult to directly use the in vitro data and baseline in vivo data for calibration of a QSP model".

To cope with the difficulties and facilitate access of QSP modelers to

  1. published in vitro and baseline in vivo data expressed in unified units (pM for molecules and kcell/L for cells),
  2. values and ranges of model parameters calculated on the basis of in vitro data, and
  3. ranges of baseline cell/cytokine concentrations estimated on the basis of in vivo human data,

InSysBio has developed 2 online databases and initiated their continuous filling with new data extracted from scientific literature:

  • fIVE (from IVitro Experiment) DB is a database collecting human quantitative in vitro data on regulations of cell dynamics processes and automatically calculating values of parameters describing the regulations of cell dynamics processes with cytokines and other molecules (https://5db.insysbio.com/).
  • CYTOCON (Cell and cYTokine CONcentration) DB is a database of human baseline concentrations of cytokines and cells measured in vivo in different tissues of healthy subjects and patients suffering from various pathologies (https://cytocon.insysbio.com/). In framework of the session we will present the tools and demonstrate how they can be used for the purposes of QSP modeling.

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

June 2020
MoTuWeThFrSaSu
1
2
1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
3
4
5
1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
6
7
8
1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
9
10
11
12
1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
13
14
15
16
17
1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
18
19
20
21
22
1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
23
24
25
26
27
28
29
30
1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
     
Upcoming Events
18.10
InSysBio to participate in ACoP 2025
Tags
Latest News
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling
25.06
InSysBio to announce extension of collaboration with discoveric bio alpha
18.06
InSysBio to publish the new article in CPT: Pharmacometrics & Systems Pharmacology
03.06
InSysBio to present Integration of Cytocon DB and fIVE DB with Heta for QSP modeling